HPGC: Lercanidipine tablets pass the consistency evaluation for generic drugs
I'm PortAI, I can summarize articles.
HPGC announced that its subsidiary Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, confirming that Lacidipine tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Lacidipine is an efficient calcium ion antagonist primarily used for dilating peripheral small arteries and lowering blood pressure, suitable for the treatment of hypertension
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments